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Background: Neuropilin 2 (NRP2) isa multi-functional co-receptor to many receptors, including VEGF receptor,
c-Met and others. NRP2 has recently been implicated in tumor angiogenesis, growth, and metastasis of many other
cancers. However, its role in osteosarcoma remains poorly understood.
Results: NRP2 was overexpressed in osteosarcoma cell lines and tissues, and associated with poor survival of
osteosarcoma patients. Knockdown of NRP2 expression by short-hairpin (Sh) RNA resulted in reduced tumor growth,
metastasis, and blood vessel formation of osteosarcoma. Knockdown of NRP2 expression by ShRNA also inhibited
the recruitment of HUVEC cells to osteosarcoma cells. Inhibition of Wnt signaling by overexpression of secreted
Wnt antagonists soluble LRP5, Frzb, and WIF1 markedly down-regulated mRNA and protein expression of NRP2 in
osteosarcoma cell lines.
Conclusions: Regulation of NRP2 receptor expression may represent a novel approach for treatment of
osteosarcoma through retarding osteosarcoma growth, metastasis and blood vessel formation. In addition,
down-regulation of NRP2 expression can be achieved by expression of secreted Wnt antagonists.
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Osteosarcoma (OS) is the most common primary malig-
nancy of bone in children and adolescents. Despite re-
cent advances in multimodality treatments consisting of
neo-adjuvant chemotherapy and wide surgical excision,
40-50% of adolescent patients develop lung metastasis
and 80% of patients with metastasis at diagnosis will re-
lapse [1]. The survival rate has not significantly changed
over past 20 years and novel therapeutic targets need to
be developed.* Correspondence: bahoang@montefiore.org
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unless otherwise stated.Neuropilins, including neuropilin-1 (NRP1) and
neuropilin-2 (NRP2), are multi-functional coreceptors
for class 3 semaphorins (SEMA) and vascular endothe-
lial growth factor (VEGF), essential for both neuronal
guidance and cardiovascular development [2,3]. NRP1-/
mice exhibited early embryonic mortality with obvious
cardiovascular defect [4]. NRP2−/− mice displayed ab-
normal development of peripheral lymph vessels [5]. In
the vascular system, NRP1 is expressed mainly in arter-
ies whileNRP2 is expressed in vein and lymphatic ves-
sels [5,6]. During angiogenesis and lymphangiogenesis,
NRP1 and 2 were involved in the regulation of endothelial
cell properties and mediate sprouting of blood vessel
and lymphatic vessels, respectively [7,8]. These findings
showed the crucial role of NRP1 and 2 in the development
of the vascular and lymphatic systems, respectively.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain








































































































































Figure 1 NRP2 expression is up-regulated in osteosarcoma cells.
(A), mRNA levels of NRP2 in normal osteoblast (NHOst) and
osteosarcoma cell lines (Saos-LM7, 143B, 143.98.2, MG-63, MNNG/HOS,
Saos-2, and U2-OS) were determined by real time PCR. (B), the protein
levels of NRP2 in NHOst and seven osteosarcoma cell lines were
detected by western blot using NRP2 antibody. The relative protein
levels were determined by densitometry and normalized with β-actin
level. (C), Kaplan-Meier survival curves of disease–specific mortality for
patients whose osteosarcoma expressed or didn’t express NRP2. The
log-rank test was used to compare differences between two groups.
NRP2 expression was predictive of poor overall survival. Significant
difference is indicated by (*) p < 0.05, (**) p < 0.01, (***) p < 0.001.
Column: mean value; Error bars: SEM
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NRP1 and NRP2 are also expressed in a wide variety of
human cancers, such as lung, breast, prostate, colon, pan-
creas, neuroblastoma, melanoma, etc. [3,9-14]. Oncologic
studies have demonstrated that over-expression of NRP1
and NRP2 is correlated with increased vascularity, meta-
static potential, advanced stage, and poor prognosis. Gen-
erally, NRP1 is predominantly found in carcinoma while
NPR2 is expressed in non-epithelial tumors, such as mel-
anoma, leukemia, neuroblastoma [15], and OS [16]. A
study by Handa et al. reported that 80% of OS samples
expressed NRP2 and NRP2-positive tumors showed a sig-
nificant increase in vascularity, and portended a poorer
prognosis [16]. However, there is still no direct evidence
that blocking NRP2 in OS results in decreased blood
vessel formation, tumor growth, or metastatic potential.
In breast [17], colorectal [18] and pancreatic cancer
[19], blocking NRP-2 resulted in suppressed tumor
growth, reduced lymphangiogenesis/angiogenesis and
metastasis, although the underlying mechanisms are
still poorly understood.
Given the implication of NRP2 in tumor growth, angio-
genesis, and metastasis, understanding the regulation of
NRP2 expression is of importance. We have reported that
blocking Wnt signaling by secreted antagonists resulted in
a suppression of tumor growth and lung metastasis
[20-24]. Angiogenesis may play a role in the regulation of
tumor growth and metastasis by the Wnt signaling path-
way. VEGF-A has been reported as transcriptional target
gene of Wnt signaling [25]. Therefore, the effects of Wnt
signaling on angiogenesis in OS and on the expression of
NRP2 deserve further exploration.
In this study, we examined the expression of NRP2 in
OS cell lines and tumor tissues, and correlated the ex-
pression levels with patients’ survival. By knocking down
NRP2 using ShRNA, we examined the potential role of
NRP2 in modulating tumor growth, invasion, metastasis
and blood vessel formation in OS. In addition, we used
Wnt antagonists as a means to elucidate the regulatory
effect of Wnt signaling on NRP2 expression.
Results and discussion
NRP2 expression is correlated with metastasis and poor
prognosis of OS
Compared to normal osteoblasts (NHOst), mRNA levels
of NRP2 are significantly increased in 6/7 OS cell lines
and protein levels are elevated in all tested cell lines
(Figure 1A & B). To examine the relationship between
NRP2 expression and disease prognosis, we performed
immunohistochemistry of NRP2 expression in OS pa-
tient samples using a tissue microarray. This array com-
prised of 24 osteoblastic, 10 chondroblastic, 19 classical,
1 fibroblastic and 1 telangiectatic OS samples. NRP2 ex-
pression was detected in 26 out of 55 samples (47.3%).Next, the cohort was dichotomized into negative and
positive NRP2-staining groups and log-rank test was
performed to compare survival. The results showed that
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0.04) (Figure 1C). Together, these data suggest a poten-
tial role for NRP2 in the pathobiology and progression
of disease in OS.
Knockdown of NRP2 by ShRNA resulted in reduced
in vitro and in vivo growth of OS
Given the high endogenous level of NRP2 in OS cells, we
performed NRP2 knockdown by ShRNA to examine its ef-
fects on the growth of OS cells. NRP2 mRNA (Figure 2A)
and protein levels (Figure 2B) were both efficiently
knocked down by ShNRP2, while NRP1 expression level
remained intact (Additional file 1: Figure S1A), suggesting
that NRP2 knockdown was specific. NRP2 knockdown
inhibited the growth of 143B cells by 23.9% (p < 0.01) at
day 2 and by 30.8% (p < 0.01) at day 3 compared to control
143B cells treated with a non-targeting ShRNA
(Figure 2C). A similar growth inhibition by ShNRP2 was
also found in Saos-2 cells (Additional file 1: Figure S1B).
We then performed soft agar assays to examine
anchorage-independent growth of tumor cells. NRP2
knockdown did not reduce the number of colony formed
by 143B and Saos-2 cells in soft agar (Figure 2D and
Additional file 1: Figure S1C). However, the colony size
was reduced (Figure 2D insert and Additional file 1: Figure
S1C insert), suggesting that ShNRP2 preferentially inhib-
ited tumor growth instead of tumorigenesis. Flow cytome-
try revealed a mild increase in the number of apoptotic
cells following NRP2 knockdown (Additional file 1: Figure
S1D). We then examined the effect of NRP2 down-
regulation on in vivo tumor growth using a xenograft
model. NRP2 knockdown in xenograft tumor samples was
confirmed by immunofluorescence (Figure 2G). As shown
in Figure 2E&F, NRP2 knockdown in OS cells has a sig-
nificant inhibitory effect on tumor growth. Compared to
the ShRNA control group, a knockdown of NRP2 reduced
tumor growth by 95.3% at day 9 (P < 0.05), 99.1% at day
12 (P < 0.01), 98% at day 15 (P < 0.05), 97.9% at day 18
(P < 0.05), and 99.2% at day 21 (P < 0.05). Interestingly, the
in vivo inhibition of tumor growth by ShNRP2 is not pro-
portional to its in vitro anti-proliferative effect, suggesting
that non-proliferative mechanisms may mediate the
in vivo effects.
NRP2 knockdown resulted in reduced tumor invasion,
migration, cell-cell adhesion, and lung metastasis in vivo
To examine the effects of NPR2 knockdown on OS cell
migration and invasion, we performed transwell motility
and Matrigel invasion assays. Both migration and inva-
sion were significantly inhibited by NRP2 knockdown in
143B and Saos-2 cells (Figure 3A&B and Additional file
1: Figure S2A,B). The levels of phosphorylated Akt and
MAPK were significantly decreased after NRP2 knock-
down (Additional file 1: Figure S2C). When tested in anorthotopic lung metastasis xenograft model, NRP2
knockdown in 143B cells led to a significant decrease in
lung metastatic nodules (Figure 3C&D). Interactions of
tumor cells with endothelial cells are known to mediate
metastasis. NRP2 has been reported to act as an adhe-
sion molecule [26], we speculated that the interaction of
OS cells and endothelial cells may promote the homing
of OS cells to the lung endothelium. Using an in vitro
cell adhesion model, NRP2 knockdown significantly im-
paired the adhesion of 143B and Saos-2 cells to the
endothelial monolayer (Figure 3E&F).
NRP2 knockdown is associated with decreased blood
vessel density in OS
Given the hypervascular nature of OS tumors and the role
of NPR2 in angiogenesis, we hypothesize that knockdown
of NRP2 expression may exert a negative effect on angio-
genesis in OS. Using an athymic nude mouse model, we
examined tumor blood vessels and capillaries in NRP2
knockdown and control tumors by anti-mouse CD31 im-
munostaining. Figure 4A showed that knockdown of
NRP2 resulted in significantly decreased blood vessel
density in NRP2 knockdown tumor (p < 0.01). Interest-
ingly, capillaries in NRP2 knockdown tumors were rarely
observed compared to those in control tumors (Figure 4A).
However, in an in vitro model, the conditioned medium
from NRP2 knockdown OS cells did not suppress HUVEC
tube formation as shown by automated quantification of
number of tubules and total tubule length (Figure 4B&C).
No significant difference was observed in the levels of
VEGF-A in the conditioned medium from control OS
cells and NRP2 knockdown cells (Additional file 1: Figure
S3). In addition, in a co-culture model, the close contact
between HUVEC and OS tumor cells did not significantly
affect the capacity for tube formation (Figure 4D). How-
ever, during co-culture, NRP2 depleted OS cells under-
went distinct morphologic change with most of the tumor
cells became round and distributed along the endothelial
tubes (Figure 4D). The significance of this change in
morphology and the underlying mechanisms remain to
be determined.
NRP2 knockdown inhibited endothelial recruitment by
OS cells
As seen in Figure 4, conditioned medium from tumor
cells with NRP2 suppression did not significantly affect
endothelial tube formation in vitro. However, ShNRP2
transfection negatively affected blood vessel formation in
the in vivo mouse model. We speculated that NRP2
knockdown in tumor cells may suppress the recruitment
of endothelial cells. To test this, we performed a trans-
well co-culture model in which NRP2 knockdown OS cells
were placed in the bottom well and HUVECs were placed



















































































143B   shCtr shNRP2
shCtr shNRP2143B

























Figure 2 NRP2 knockdown inhibited both in vitro and in vivo tumor growth. (A & B), NRP2 expression was knocked down by NRP2 shRNA in
143B cells. Knockdown efficiency was determined by real-time PCR (A) and Western blotting (B). (C), By MTT assay, NRP2 knockdown suppressed
anchorage-dependent growth of osteosarcoma 143B cells. (D) Soft agar assay. NRP2 knockdown did not reduce the number of colony formed by
143B cells. 143B cells transfected with ShNRP2 formed smaller colony than control vector transfected cells as shown in the representative images
of soft agar (insert). (E) & (F) NRP2 knockdown inhibited the in vivo tumor growth in xenograft nude mice model. 1 × 106143B cells were inoculated in
NCR nu-nu nude mice. Tumor size was measured every 3 days and a tumor growth curve was created (E). Points, mean tumor volume; Bars, SEM.
(F), Representative picture of tumor harvested at day 21. (G), the knockdown of NRP2 expression in tumor samples was confirmed by immunofluorescence
staining using NRP2 antibody. Significant differences are indicated by: (*) p < 0.05, (**) p < 0.01. Column: mean value; Error bars: SEM.
Ji et al. Molecular Cancer  (2015) 14:86 Page 4 of 14less HUVECs in NRP2 knockdown group migrated
through the porous insert than those in the control group
(Figure 5A&B). In addition, decreased recruitment of
HUVEC was observed in both Matrigel coated and un-
coated inserts, suggesting that migration and invasion of
endothelial cells were inhibited by NRP2 knockdown in
tumor cells (Figure 5A&B). These findings suggest thatinhibition of vessel formation in ShNRP2 tumors may be
mediated by decreased endothelial recruitment.
NRP2 expression is regulated by canonical Wnt signaling
Genechip® microarrays showed that blocking canonical
Wnt signaling by a soluble LRP5 receptor (sLRP5)
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Figure 3 Knockdown of NRP2 inhibited the tumor invasion, migration and lung metastasis of osteosarcoma. (A), Migration assay. The BD
chamber system without Matrigel coating was used to evaluate the migration of shNRP2 and control vector transfected osteosarcoma 143B cells.
The migration of 143B cells was significantly inhibited by NRP2 knockdown. (B), Matrigel invasion assay was performed in BD chamber system
coated with Matrigel, using shNRP2 and control vector transfected osteosarcoma 143B cells. There were less NRP2 depleted 143B cells invaded
through the matrigel coated porous membrane. (C), Knockdown of NRP2 in 143B cells reduced the lung metastasis of osteosarcoma in an
orthotopic lung metastasis mouse model. Mouse lungs were fixed in Bouin’s solution, and the number of lung surface metastatic nodules was
counted and graphed. Each group contained 10 mice and the experiment was repeated 3 times (D), Representative photographs of lungs with
metastatic nodules of osteosarcoma. (E), NRP2 knockdown significantly reduced both 143B and Saos-2 cells adherence to the endothelial
monolayer. The mean cell number was calculated from 10 fields (×100). (F), Representative images of GFP transfected tumor cells adhering to the
endothelial monolayer. Significant differences are indicated by: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001. Column: mean value; Error bars: SEM.
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time PCR (Figure 6B) and western blot (Figure 6C & D).
These results suggest that NRP2 is negatively regulated by
secreted Wnt antagonists. Over-expression of the Wnt an-
tagonist DKK3 or Wif-1 in Saos-2, 143B, U2OS cells re-
sulted in reduced expression of NRP2 (Figure 6E). These
findings implicate NRP2 as a potential Wnt target gene in
OS. By using Genebank and MatInspector software, five
putative TCF4 binding sites were identified in the NRP-2
promoter (Figure 6G). Chromatin immunoprecipitation
(ChIP) assays were performed to determine whether these
sites are capable of binding TCF. An anti-TCF4 antibody
was used to immunoprecipitate DNA fragments that canbind TCF4. These fragments were then amplified using
primers spanning each of the five TCF binding sites. As
shown in Figure 6F, TCF4 bound all five binding sites in
NRP2 promoter region, suggesting that NRP2 is a poten-
tial transcriptional target of canonical Wnt signaling.
Discussion
In the present study, we show that NRP2 is significantly
elevated in OS cell lines compared to normal osteoblasts.
Furthermore, the expression of NRP2 correlates with a
poor prognosis of OS patients. To the best of our know-
ledge, this study also represents the first line of evidence

















shCtr shNRP2 shCtr shNRP2
143B Saos-2





































143B  shCtr shNRP2
**
143B shCtr 143B shNRP2
143B Saos-2





Figure 4 (See legend on next page.)
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Figure 4 Knockdown of NRP2 resulted in decreased blood vessel density of OS in vivo. (A), Blood vessels (top panel) and capillaries (bottom
panel) in tumor samples were visualized by immunohistochemistry with CD31 antibody. Tumor cell nuclear was stained with DAPI. Number of
blood vessels per field (100×) was calculated and graphed (Right). Column, mean number of blood vessel per field (x100); Error bars, SEM.
(B & C), Matrigel tube formation assay: no difference was found in the number of tubules formed by HUVEC in conditioned medium from
shNRP2 OS cells and shRNA control cells. (B) Representative photographs of tubules formed by HUVEC cells on Matrigel. (C) The tubular number
was calculated and graphed, Column: mean number of tubules; Error bars: SEM. (D), tumor-endothelial co-culture tube formation assay: The
HUVEC cells were stained with CellTracker Red CMTPX dye and the tumor cells were transfected with shNRP2 vector with GFP expression. Left panel:
tubules formed by HUVEC (red); middle panel: tumor cells (green) attached on tubules; right panel: merged image (right) of HEVEC tubules (red) and
attached tumor cells (green). NRP2 depleted tumor cells sustained distinct morphologic changes compared to control cells (bottom panel).
Ji et al. Molecular Cancer  (2015) 14:86 Page 7 of 14Wnt signaling pathway. Our in vitro data suggest that
NRP2 modulates the recruitment of endothelial cells as a
means to enhance tumor angiogenesis. Our in vivo experi-
ments corroborate these data by demonstrating that inhi-
biting NRP2 by ShRNA impairs blood vessel formation,
tumor growth, and metastatic potential of OS. These data
suggest that NRP2 serves a tumor promoting function in
OS. Therefore, suppression of NRP2 may be a novel strat-
























































Figure 5 NRP2 knockdown suppressed endothelial recruitment by osteosa
endothelial cells migrated through the porous insert membrane of the Cham
osteosarcoma cells vs control cells were seeded in the lower chamber. HUVEC
photograph of migrated HUVECs. (B), in a trans-well co-culture invasion mode
membrane of the Chamber in shNRP2 group compared to control group. shN
lower chamber. HUVECs were seeded in the top insert chamber. Insert picture
are indicated by: (*) p < 0.05, (**) p < 0.01. Column: mean migrated/invaded ceKnockdown of NRP2 by ShRNA only resulted in a
moderate inhibition of in vitro cellular growth and a
mild apoptotic effect in OS. However, NRP2 knockdown
significantly abrogated the in vivo growth of OS tumors
in a mouse model. These findings indicate that the ef-
fects of NRP2 knockdown in vivo is not a direct result of
inhibiting tumor cell proliferation. Interestingly, our
study showed that tumor samples from the ShNRP2
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rcoma cells. (A), in a trans-well co-culture migration model, less
ber in shNRP2 group compared to control group. shNRP2 depleted
s were seeded in the top insert chamber. Insert picture: Representative
l, less endothelial cells invaded through the matrigel coated porous insert
RP2 depleted osteosarcoma cells vs control cells were seeded in the
: Representative photograph of invaded HUVECs. Significant differences
lls per field (40×); Error bars: SEM.
Figure 6 NRP2 expression is regulated by Wnt signaling pathway. A, Genechip® microarray showed the down-regulated expression of NRP2 in
Wnt antagonist sLRP5 transfected osteosarcoma Saos-2 cells. VEGF expression is intact. Real time PCR (B) and western blot (C) with accompanying
densitometric assay (D) confirmed the down-regulated mRNA and protein level of NRP2 in Wnt antagonist sLRP5 transfected Saos-2 cells, while
VEGF level remains intact. E, western blot and accompanying densitometry showed the down-regulated NRP2 expression in additional Wnt
antagonist DKK3 transfected Saos-2 cells, 143B cells and U2-OS cells, and Wif-1 transfected 143B cells. F, Chromatin immunoprecipitation (ChIP)
assay verified the binding of TCF4 on the five binding sites in NRP2 promoter region. G, schematic representation of the binding sites of TCF/LEF
on the 3-kb promoter region of NRP2 genes.
Ji et al. Molecular Cancer  (2015) 14:86 Page 8 of 14NRP2 enhances blood vessel formation in OS. This find-
ing is consistent with previous reports in breast [17],
colorectal [18], and pancreatic cancer [19]. However,
none of those reports investigated the interaction of
NRP2 suppressed tumor cells and endothelial cells. Inthis study, we used tumor cell-HUVEC co-culture model
to examine the effect of NRP2 knockdown in tumor cells
on HUVEC tube formation and recruitment. Unexpect-
edly, knockdown of NRP2 in OS cells preferentially in-
hibit the recruitment of HUVEC rather than inhibiting
Ji et al. Molecular Cancer  (2015) 14:86 Page 9 of 14the capacity of HUVEC to form endothelial tubes. To
the best of our knowledge, NRP2-mediated endothelial
recruitment by OS cells represents a novel finding in
this study as this phenomenon has not been well de-
scribed. Vascular endothelial cells recruitment plays a
pivotal role in vessel sprouting and angiogenesis [27].
Blocking recruitment of endothelial progenitor cells by
anti-angiogenic drugs has been associated with a reduc-
tion in tumor size and blood flow [28]. Molecular mech-
anisms underlying endothelial cell recruitment by NRP2
in tumor cells remains to be explored.
VEGF, SDF-1 [29], and CXC chemokine [30] have
been reported to mediate angiogenesis including endo-
thelial cell recruitmeng [29]. In the present study, our
data indicated that NRP2 knockdown did not affect the
secretion of VEGF from tumor cells. A series of other
soluble factors deserve further exploration. In addition,
the recruitment of angiocompetent BMDCs (bone-mar-
row-derived dendritic cells), TEMs (Tie2-expressing
monocyte), TAMs (Tumor-associated macrophages), neu-
trophils, mast cells and CD11b +GR-1 +myeloid-derived
suppressor cells, which release angiogenic factors such as
VEGF, and MMP [31] may also play an important role in
endothelial recruitment and angiogenesis in tumor. The
recruitment of angiocompetent immune cells by NRP2 de-
pleted tumor cells deserves further study as well.
Tumor-endothelial communication has mutual influ-
ence on both sides. Our data showed that NRP2 knock-
down in tumor cells not only changed the behavior of
tumor cells but also altered the interaction between OS
and endothelial cells. Interestingly, during co-culture
with endothelial cells, the NRP2-suppressed OS cells de-
veloped significant morphological change. The signifi-
cance and mechanism underlying the morphological
change of Sh-NRP2 cells remains to be explored. Our pre-
vious study demonstrated decreased metastatic capacity of
morphologically changed OS cells by Wnt antagonists
[22,32]. Further experiments are needed to determine if
the co-culture and NRP2 knockdown induced OS cell
morphology change is one of the mechanisms that re-
sulted in the decreased lung metastasis in OS.
Pulmonary metastasis represents a poor prognostic
factor that still remains as a therapeutic bottleneck in
OS. NRP2 expression has been shown to correlate with
aggressiveness and metastasis of several types of malig-
nancy [3]. In this study, our tissue microarray data
clearly shows that NRP2 expression correlates with a
worse prognosis, strongly implicating its role in OS pro-
gression and metastasis. NRP2 knockdown in OS cells
exhibited reduced motility and invasion, suggesting a
direct effect of NRP2 on metastatic capacity of OS cells.
Others have shown that NRP2 promotes extravasation
and metastasis in renal cell carcinoma by interaction
with endothelial α5 integrin [26]. Here, our in vivostudies demonstrated that NRP2 knockdown signifi-
cantly inhibited pulmonary metastasis of OS in a xeno-
graft mouse model. Cancer cell adhesion involves
interacting with adjacent cancer cells as well as endothe-
lial cells and extracellular matrix. NRP1 was initially
identified as a cell-cell adhesion molecule [33]. There-
fore, it is of interest to determine whether NRP2 is in-
volved in cancer to endothelial cell adhesion. Goel and
colleagues reported that NRP2 regulated α6β1 integrin
and enabled the formation of focal adhesion of breast
cancer [34]. Cao et al. used atomic force microscopy to
precisely measure the attachment and detachment of
cancer cells to endothelial cells via NRP2 binding to α5
integrin [26]. Using endothelial adhesion assays, we dem-
onstrated that NRP2 is required for OS cell adhesion to
endothelial cells, consistent with recent reports in the lit-
erature. Clearly, findings from this study and others have
deepened our understanding of the important role of
NRP2 in tumor metastasis, indicating its potential as a
novel therapeutic target.
VEGF-A has been reported as a transcriptional target
of Wnt signaling in colon cancer [25]. Unlike NRP2, we
found that VEGF-A expression was not suppressed in OS
cells by the Wnt antagonist sLRP5. Due to diverse func-
tions of Wnt antagonists, we also sought to use other se-
creted antagonists to examine the consequence of Wnt
blockade on NRP2. Blocking Wnt signaling by additional
antagonists such as Wif-1 and DKK3 led to a similar sup-
pression of NRP2, strongly implicating this receptor as a
downstream Wnt target. Furthermore, chromatin IP as-
says confirmed the existence of TCF-binding sequences
within 3kbp upstream of the transcription start site for
the NRP2 gene. These regions presumably function as
transcriptional regulatory elements. Whether the NRP2
promoter responds to the β-catenin/TCF complex still
remained undetermined. However, these findings sug-
gest a novel role for Wnt signaling as a modulator of
tumor angiogenesis by regulating NRP2.
In this study, we found that blocking Wnt signaling
by DKK3 resulted in variable inhibitory effects on NRP2
in different OS cell lines. The reason for this variation
may be related to the ability of Dkk-3 to inhibit Wnt
signaling being cellular context-dependent. We previ-
ously demonstrated Wnt inhibition by DKK3 in OS
Saos-2 cells as evidenced by antagonism of cytoplasmic
β-catenin [22]. However, ectopic Dkk-3 expression in
prostate cancer cells activates c-Jun NH2-terminal kin-
ase (JNK) leading to apoptosis but did not affect β-
catenin level, suggesting a role for Dkk-3 in the Wnt/
PCP rather than in the Wnt/β-catenin pathway [35].
Despite this variation, secreted Wnt antagonists appear
to down-regulated NRP2 expression in OS cells, sug-
gesting that Wnt signaling modulates tumor angiogen-
esis via NRP2.
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We demonstrated that inhibition of NRP2 expression by
shRNA knockdown impaired tumor growth, invasion,
and blood vessel formation in OS. NRP2 modulates
tumor blood vessel formation by altering the recruit-
ment of endothelial cells to OS tumor cells. In addition,
NRP2 can be down-regulated by overexpression of se-
creted Wnt antagonists such as sLRP5, Frzb, and WIF1.
Our study also suggests that NRP2 expression is tran-
scriptionally regulated by canonical Wnt signaling.
Methods
Cell lines and plasmids
Normal Human Osteoblasts (NHOST) were obtained
from Cambrex Bio Science and maintained in Osteoblast
Growth Media (Lonza). Saos-LM7 was a gift from Dr.
Eugenie Kleinerman (MD Anderson Cancer Center,
Houston, TX). Human OS cell lines 143B, 143.89.2,
Saos-2, MNNG/HOS and U2OS (American Type Culture
Collection), Saos-LM7, and OS160 were maintained in
MEMα medium supplemented with 10% fetal bovine
serum (FBS), supplemented with penicillin/streptomycin.
Human Umbilical Vein Endothelial Cells (HUVEC) were
from ATCC (American Type Culture Collection, Manassas
VA) and maintained in EGM-2 medium supplemented with
2% FBS and VEGF. All cells were cultured at 37°C in a hu-
midified incubator with 5% CO2. PCDNA3.1 Directional
TOPO Expression vector was obtained from Invitrogen. An
Ultimate ORF WIF-1 clone (ID: IOH11153) was obtained
from Invitrogen and subcloned into the PCDNA3.1 TOPO
vector. The dominant-negative, soluble LRP5 plasmid
(sLRP5, a generous gift of Matthew Warman, Case Western
Reserve University, Cleveland, OH), was constructed by de-
leting the transmembrane and cytoplasmic domains of
LRP5, resulting in a secreted protein that binds and prevent
Wnt ligands from activating the native LRP5 receptor.
Tissue microarrays (TMA) and survival analysis
Patient OS tissue microarrays (TMA) were purchased
from IMGENEX. NRP-2 staining was conducted by
using rabbit anti-NRP2 antibody and anti-rabbit immu-
nostaining kit from R&D system. NRP2 staining inten-
sity of the tumor tissue was scored as no staining (−),
weak staining (+), moderate staining (++), and strong
staining (+++). The clinical information of tissue micro-
array samples included follow-up duration and survival
status. Kaplan-Meier survival curve was created to rep-
resent disease–specific mortality for patients with or
without NRP2 expression. The log-rank test was used to
compare differences between two groups.
RNA interference
For NRP2 knockdown experiment, OS cell lines were
transfected with Lipofectamine 2000 (Life Technologies)with pGFP-V-RS HuSH shRNA vectors (Origene) con-
taining either the scrambled shRNA cassette TR30013
(control) or human NRP2 targeting shRNAs. 143B or
Saos-2 cells constitutively expressing the puromycin re-
sistance gene and human NRP2 shRNA were selected
and expanded in media containing 1 μg/mL puromycin.
The pooled stable transfectants (to avoid cloning arti-
facts) were examined.RNA isolation and real time quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. Reverse tran-
scription of total RNA was performed using the Reverse
Transcription System kit (Promega, Madison, WI) with
random primers. Real-time RT-PCR was performed as
previously described [21]. PCR condition was as follows:
45 cycles of 30 seconds at 95°C, 30 seconds at 58°C, 60 sec-
onds at 72°C. Relative fold change in mRNA expression
compared to control was calculated using the comparative
Ct method. Ct is the cycle number at which fluorescence
intensity first exceeds the threshold level. Δ Ct is Ct (target
gene) -Ct (actin). Gene-specific primer sequences are
available upon request. Specificity of amplification prod-
ucts were verified by agarose gel electrophoresis and melt-
ing curve analysis [24].Western blot
Twenty to 80 μg of protein lysate was separated electro-
phoretically on denaturing SDS-polyacrylamide gel,
transferred to nitrocellulose membranes, and probed
with primary antibodies. Blots were exposed to horse-
radish peroxidase-conjugated secondary antibodies and
visualized by an ECL detection system according to the
manufacturer’s protocol (Amersham Biosciences, Piscat-
away, NJ). For loading control, the initial western blot
was placed in Restore Western stripping buffer (Thermo
Scientific) for 15 min to remove the antibody (primary
and secondary), washed in water for 5 min, blocked with
5% milk for 1 hour, and probed with β-actin antibody
(Santa Cruz Biotechnology, Santa Cruz, CA; Catalog #
sc-130301) [20,24]. The primary antibodies used in west-
ern blot included NRP2, GAPDH (Santa Cruz Biotech-
nology, Santa Cruz, CA. NPR2 catalog # sc-13117;
GAPDH catalog # sc-137179); VEGF, DKK3 (Abcam,
Cambridge, MA. VEGF catlog # ab46154; DKK3 catalog
# ab136101); Wif-1 (Cell Signaling Technology, Danvers,
MA, Catalog # 5652); Each western blot was repeated 3
times. Blots were quantitated by densitometry using
Image J (Software, NIH, Bethesda, MD, USA) and nor-
malized to a housekeeper marker β-actin or GAPDH
[36]. The intensity of each tested marker is presented as
a ratio of a tested mark/β-actin or GAPDH.
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Tumor and lung tissues were fixed in formalin and sec-
tioned. Antigen retrieval was done using 10 mmol/L so-
dium citrate (pH 6.0) at 95°C for 15 min. After blocking
with PBS containing 3% bovine serum albumin for 1 h,
cells were incubated with an NRP2 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, Catalog# sc-13117) for
12 h. After washing, cells were incubated with an Alexa-
488 conjugated secondary antibody (Molecular Probes,
Eugene, OR, Catalog # A-11059) and mounted in Vecta-
shield with 4’, 6-diamidino-2-phenylindole (DAPI, Vector
Laboratories, Burlingame, CA). Localization of immuno-
staining was analyzed by laser scanning confocal micros-
copy (X40 magnification) using the 488-excitation
wavelength [32].
Flow cytometry
For apoptosis detection, cells were stained with FITC-
labeled annexin V and propidium iodide (PI) (BD Biosci-
ences, San Jose, CA). After incubations, floating cells
were first harvested and adherent cells were trypsinized
and pooled together. Cells were washed twice with cold
PBS and resuspended in 1× binding buffer at a concen-
tration of 1 × 106 cell/ml. Transfer 100ul of the solution
(1 × 105 cells) to a 5 ml culture tube. Add 5ul of FITC
Annexin V and 5ul PI. Gently vortex the cells and incu-
bate for 15 min at room temperature in the dark. After
the incubation period, 400ul of 1 × binding buffer was
added to each tube. The stained cells were analyzed by
flow cytometry in one hour. Each flow-cytometry experi-
ment was repeated three times [37].
Blood vessel density assay
Immunofluorescence was used to determine blood vessel
density with CD31 (Abcam), a marker for vascular endo-
thelium, and the blood vessel staining was analyzed with
a Nikon Eclipse TE2000-S fluorescent microscope (mag-
nification, 100X) using the 488-excitation wavelength.
The vessel density was determined by counting the
number of blood vessels in 10 fields (magnification,
100X) of slides from each group and the result was re-
corded as mean number of blood vessels per field.
Motility and invasion assay
Motility and invasion assays were performed using 24-
well invasion chamber system (BD Biosciences, MA) as
previously described [21]. The matrigel coated inserts
were used for invasion assay. The uncoated inserts were
used for motility assay. 1 × 105 cells for invasion assay
and 5 × 104 cells for motility assay were seeded in the
upper chamber in serum-free MEMα medium. MEMα
medium with 10% FBS (used as a chemoattractant) was
placed in the bottom well. Incubation was carried out
for 48 h for invasion assay or 24 h for migration assay,at 37°C in humidified air with 5% CO2. Non-invasive or
non-migrating cells in the upper chamber were then re-
moved with a cotton swab. Invading or migrating cells
on the bottom of the inserts were fixed with methanol
and stained with hematoxylin. The number of invading
or migrating cells was determined by counting five fields
(100×) under the microscope, and calculated as mean
number of cells per field. All experiments were per-
formed in triplicate.
Endothelial recruitment
Twenty thousand tumor cells were seeded into 24-well
plates approximately 24 h before the start of the recruit-
ment assay. HUVEC cells were serum starved in EGM-2
medium supplemented with 0.2% FBS for 24 h. HUVEC
cells were then suspended at 4 × 104 HUVECs per ml of
0.2% FBS EGM-2. 500 μl of the suspension was then
added into each insert and the recruitment assay was
allowed to proceed for 12–16 h depending on tumor cell
lines. After completion of the assay, the inserts were fixed
with methanol for 5 min and stained with hematoxylin.
The number of migrating or invading cells was deter-
mined by counting 5 fields at × 100 magnification.
Endothelial adhesion assay
HUVEC cells were cultured in 6-well plate and allowed
to grow to confluence. 2 × 104 tumor cells were added
into the wells pre-cultured HUVEC cells for 30 minutes
at 37°C. The wells were washed with PBS gently to re-
move non-adherent cells. Five images were taken. The
number of tumor cells adhering to the HUVEC cell was
then quantified using ImageJ (NIH).
Soft agar colony formation assay
Soft agar colony formation assay was performed using
six-well plates as previously described [24]. Each well
contained 2 mL of 0.8% agar in complete medium as the
bottom layer, 1 ml of 0.35% agar in complete medium
and 6000 cells as the feeder layer, and 1 ml complete
medium as the top layer. Cultures were maintained
under standard culture conditions. The number of col-
ony was determined with an inverted phase-contrast
microscope at × 100 magnification. A group of >10 cells
was counted as a colony. The data are shown as mean
number of colony ± SEM of four independent wells at
20 days after the start of cell seeding [24].
In vivo tumorigenesis model
4-week old male nu/nu nude mice (Taconic) were pur-
chased and housed in pathogen-free conditions for add-
itional 4 weeks before tumor inoculation. The animal
protocol was approved by the Institutional Animal Care
Utilization Committee (IACUC). Sh-NRP2 transfected
and vector control transfected 143B cells were grown to
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subcutaneously (S.C.) into the flank of 8-week old nude
mice at 1 × 106 cells/0.1 ml. Tumor size was measured
every 3 days using a caliper. The tumor volume was cal-
culated by the formula 1/6 πab2 (π =3.14, a = long axis
and b = short axis of the tumor). Growth curves were
plotted from the mean tumor volume ± SEM from 10
animals in each group. 21 days after injection, the ani-
mals were sacrificed and tumors were harvested, mea-
sured, weighed, and fixed in 10% formalin [20,24]. Each
experiment was repeated 3 times.
In vivo lung metastasis model
4-week old male nu/nu nude mice (Taconic) were were
purchased and housed in pathogen-free conditions for
additional 4 weeks before tumor inoculation. shNRP2
transfected and vector control transfected 143B cells
were grown to 80% confluence, and re-suspended in
PBS. 0.03 ml of cell suspension (1 × 107 cells/ml) was
injected percutaneously into the tibia of anesthetized 8-
week old nude mice. After 4 weeks, the animals were
sacrificed according to an IACUC-approved protocol.
Lungs were harvested, fixed in Bouin’s solution, and the
number of lung surface metastatic nodules was counted
and graphed. To determine the number of lung surface
metastatic nodules per field, we count 10 fields (×100)
to calculate the mean value for each group. Mean num-
ber of lung nodules was compared between shNRP2
transfected and vector control transfected groups. Each
group contained 10 mice and each experiment was re-
peated 3 times. Microscopic lung metastases were visu-
alized on 5-μm paraffin embedded sections stained with
H & E [20].
HUVEC Tube Formation Assay
In order to examine the effect of NRP2 knockdown on
angiogenesis, matrigel tube formation assay was per-
formed using Human Umbilical Vein Endothelial Cells
(American Type Culture Collection, Manassas VA).
Tube formation assay was performed according to the
manufacturer’s protocol (BD, Endothelial Cell Tube
Formation Assay). Briefly, HUVEC cells were serum
starved in EGM-2 media supplemented with 0.2% FBS
for 24 h. 96-well culture plates were coated with 50 μl
Matrigel (BD Biosciences, San Hose, CA), that was
allowed to solidify for 1 hour at 37°C. The pre-treated
HUVEC cells were then seeded in the well at 3 × 104
cells/well. Meanwhile, the conditioned medium was col-
lected and added in each wells. Then the HUVEC cells
were incubated at 37°C for 6 hours. For tumor cell-
HUVEC co-culture model, HUVEC cells were labelled
with CellTracker Red CMTPX dye (Invitrogen) for
30 min and subsequently treated in EGM-2 media sup-
plemented with 2% FBS for 30 min. The tumor cells andHUVEC cells were trypsinized and re-suspended at 4 ×
104/ml and 2 × 105/ml respectively in EGM-2 media
supplemented with 2% FBS. The tumor and HUVEC
cell suspensions were then mixed at a 1:1 ratio and
100 μl of each mixture was seeded into each well of the
tube formation assay plate. The assay plate was incu-
bated at 37°C for 12 h. Images of each well were taken
and processed using Angiogenesis Analyzer for ImageJ
software (NIH) to obtain the number of tubules and
total tubule length per image.Chromatin immunoprecipitation (ChIP) analysis
By analysis of promoters using Genebank and MatIn-
spector software, five TCF/LEF binding sites in NRP2
promoter region were found. In order to verify the bind-
ing of TCF/LEF on NRP2 promoter region, Chromatin
immunoprecipitation (CHIP) analysis was performed
using Upstate Chromatin immunoprecipitation (CHIP)
Assay Kit (Millipore, San Diego, CA). Briefly, 1x106
143B cells were seeded in 10 cm dish. After overnight
incubation, 1% formaldehyde was directly added to the
culture medium and incubated for 10 minutes at 37°C to
cross link histones to DNA. Cells were then lysed and
sonicated to shear DNA to between 200–1000 base
pairs. TCF4 antibody (3 μg/mL) was added and incu-
bated overnight with rotation. 60 μL Protein A Agarose
was added to precipitate the DNA/antibody complex.
After sequentially washing with low salt immune com-
plex wash buffer, high salt immune complex wash buf-
fer, LiCl immune complex wash buffer, and TE buffer,
DNA/antibody complex was eluted from antibody. After
histone-DNA crosslink at 65°C for 4 h, DNA was recov-
ered by phenol/chloroform extraction and ethanol pre-
cipitation. Polymerase chain reaction (PCR) was
performed to amplify the TCF/LEF binding sites. Five
pairs of primer for NRP2 promoter, which span each
TCF/LEF binding site, were used. The primer sequences
are available upon request.Statistical analysis
Comparisons of number of colony, fold change in levels
of mRNA, and the blood vessel density between differ-
ent transfection groups were conducted using Student’s
t-test. For tumor growth experiments, repeated mea-
sures ANOVA was used to examine the differences in
tumor volume among different transfection groups at
each time points. Additional post-test was done to
examine the differences in tumor volume between vec-
tor control and Sh-NRP2 transfection groups at each
time point by the conservative Bonferroni method. All
statistical tests were two sided. P < 0.05 was considered
statistically significant.
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Additional file 1: Figure S1. NRP2 knockdown inhibited in vitro tumor
growths. (A), NRP2 expression was specifically knocked down by NRP2
shRNA in 143B and Saos-2 cells, while NRP1 level was intact. Knockdown
efficiency was determined by Western blotting and quantified by
densitometric assay. (B), By MTT assay, NRP2 knockdown suppressed
anchorage-dependent growth of Saos-2 cells. (C), Soft agar assay.
NRP2 knockdown didn’t significantly reduce the number of colony
formed by Saos-2 cells, but decreased the size of colony as shown in
the representative images of soft agar (insert). (D) There were slightly
higher percentage of early and late apoptosis in shNRP2 OS cells, compared
to control cells. Figure S2. NRP2 depletion significantly suppressed
migration and invasion of Saos-2 cells. (A), Migration assay. The BD chamber
system without Matrigel coating was used to evaluate the migration of
osteosarcoma Saos-2 cells transfected with shNRP2 and control vector. (B),
Matrigel invasion assay was performed in BD chamber system coated with
Matrigel, using shNRP2 and control vector transfected osteosarcoma Saos-2
cells. (C), Western blot and accompanying densitometry demonstrated the
inhibition of AKT and MAPK phosphorylation by NRP2 knockdown in 143B
cells. Figure S3. ELISA demonstrated no difference of VEGF-A level in the
condition medium from shNRP2 and control vector transfected 143B cells.
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